There is one clinical trial.
A randomized, double-blind, placebo-controlled, clinical trial of LY3127804 in participants who are hospitalized with pneumonia and presumed or confirmed COVID-19. The study may last up to 9 weeks and include daily visits up to day 28, and follow-up visits by phone.
Description: Number of days on which a participant breathes without assistanceMeasure: Number of Ventilator Free Days Time: Day 1 to Day 28
Description: The scale is an assessment of clinical status. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activitiesMeasure: Number of Participants Reporting Each Severity Rating on the National Institute of Allergy and Infectious Diseases (NIAID) Ordinal Assessment Time: Day 1 to Day 28
Description: Survival without Respiratory FailureMeasure: Percentage of Participants who are Alive and Respiratory Failure Free Time: Day 1 to Day 28
Description: MortalityMeasure: Mortality Time: Day 1 to Day 28
Description: Days of HospitalizationMeasure: Length of Hospitalization Time: Day 1 to Day 28
Description: Number of Participants with any Serious Adverse Event (SAE)Measure: Number of Participants with any Serious Adverse Event (SAE) Time: Day 1 to Day 28
Description: Number of Participants with any Treatment Emergent Adverse Event (TEAE)Measure: Number of Participants with any Treatment Emergent Adverse Event (TEAE) Time: Day 1 to Day 28
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports